Table 2.
Pathological and oncologic outcomes.
| Median followup (months) | 34 (2–66) |
| Pathological stage (%) | |
| pT2a-bN0 | 33 (15.1%) |
| pT2cN0 | 103 (47.2%) |
| pT3aN0 | 27 (12.4%) |
| pT3bN0 | 36 (16.5%) |
| pT4N0 | 9 (4.2%) |
| pT1-4N1 | 10 (4.6%) |
| Pathological Gleason sum (%) | |
| <7 | 52 (23.9%) |
| = 7 | 145 (66.5%) |
| 3 + 4 | 87 |
| 4 + 3 | 58 |
| >7 | 21 (9.6%) |
| Positive surgical margins (%) | |
| Overall | 59 (27.1%) |
| pT2 | 20 (14.6%) |
| pT3 | 35 (48.6%) |
| pT4 | 4 (44.4%) |
| Perineural invasion (%) | |
| Overall | 136 (62.4%) |
| pT2 | 64 (47.1%) |
| pT3/4 | 62 (45.6%) |
| pN1 | 10 (7.3%) |
| PSA recurrence (%) | |
| Overall | 25 (13.1%) |
| pT2 | 10 (7.3%) |
| pT3a | 4 (14.8%) |
| pT3b | 9 (25.0%) |
| pT1-4N1 | 2 (20.0%) |